Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.244 EUR -2.4% Market Closed
Market Cap: 30.4m EUR

Wall Street
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.

Lowest
Price Target
0.364 EUR
49% Upside
Average
Price Target
0.388 EUR
59% Upside
Highest
Price Target
0.42 EUR
72% Upside
Gensight Biologics SA Competitors:
Price Targets
VTGN
VistaGen Therapeutics Inc
388% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
35% Upside
MREO
Mereo Biopharma Group PLC
199% Upside
VITR
Vitrolife AB
56% Upside
SANION
Saniona AB
55% Upside
DSGN
Design Therapeutics Inc
51% Upside
4891
TMS Co Ltd
290% Upside
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
3% Downside

Revenue
Forecast

Revenue Estimate
Gensight Biologics SA

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 54%.

N/A
Past Growth
54%
Estimated Growth
Estimates Accuracy
-54%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Gensight Biologics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-72%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SIGHT's stock price target?
Price Target
0.388 EUR

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.388 EUR with a low forecast of 0.364 EUR and a high forecast of 0.42 EUR.

What is Gensight Biologics SA's Revenue forecast?
Projected CAGR
54%

The compound annual growth rate of Gensight Biologics SA's revenue for the next 3 years is 54%.

Back to Top